Cyberknife radiosurgery for trigeminal schwannomas.

Autor:	Sakamoto GT; Department of Neurosurgery, Stanford University Medical Center, Stanford, California 94305, USA. gsaka@stanford.edu, Borchers DJ 3rd, Xiao F, Yang HJ, Chang SD, Adler JR Jr
Jazyk:	angličtina
Zdroj:	Neurosurgery [Neurosurgery] 2009 Feb; Vol. 64 (2 Suppl), pp. A14-8.
DOI:	10.1227/01.NEU.0000341629.57676.DB
Abstrakt:	Objective: Trigeminal schwannomas (TS) are benign tumors that are managed by surgical resection and/or stereotactic radiosurgery. Most radiosurgical series report results using the gamma knife. The CyberKnife (Accuray, Inc., Sunnyvale, CA) is a frameless, robotic stereotactic radiosurgical system. In this series, we report our experience using the CyberKnife in the treatment of TS. Methods: We retrospectively reviewed the medical records and diagnostic imaging in 13 consecutive patients with TS who were treated with the CyberKnife from 2003 to 2007. Seven patients had a previous surgical resection. The mean tumor volume was 6.3 mL (range, 0.39-19.98 mL), and the mean marginal dose was 18.5 Gy. Six of the tumors were treated in a single session. The mean clinical follow-up period was 21.8 months (range, 7-53 months). Results: In this series, the tumor control rate was 100%. The average reduction in tumor volume was 45% (range, 14-98%). A modest improvement in facial pain was noted in 4 of the 6 patients who presented with this symptom. One patient had improvement in facial numbness, and another had improvement in pretreatment headaches. One patient developed jaw weakness and facial dysesthesia, and another patient developed asymptomatic radiation necrosis. Conclusion: Although the length of follow-up is limited, we report our initial experience with CyberKnife treatment of TS. Our results demonstrate tumor control rates and clinical outcomes that parallel those of previous reports using gamma knife radiosurgery; however, long-term follow-up studies are needed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu